Staff Reports
The new Council on Foreign Relations study known as “The Pharma Choke Point” has shoved a quiet crisis into the open. The report warns that America now depends on Chinese firms not just for cheap chemical ingredients, but for biologics, synthetic DNA tools and even late-stage drug work. In plain English: Beijing could, if it wanted, turn our medicine supply chain into a lever against the United States. That is the development everyone in Washington is suddenly waking up to — and they should be angry they slept on it.
What the CFR report actually found
The CFR study maps where U.S. drugs and biotech now rely on China. It points to real things: APIs once made mostly overseas, rapid growth in Chinese biologics programs, and more clinical trials and manufacturing happening in China than before. The report even compares the risk to the rare-earths problem — meaning the U.S. could be left scrambling if supply is cut or controlled. Those are not wild guesses. They are measurable trends that show a growing choke point in our medicine supply.
How China could weaponize biotech — without firing a shot
“Weaponize” is a scary word, so let’s be clear: the CFR and the National Security Commission on Emerging Biotechnology use it as a warning. They mean Beijing could use export rules, slow approvals, quality delays or legal pressure to disrupt drug supplies or stall new treatments. That doesn’t look like a headline biological attack. It looks like a slow pinch: hospitals run low, clinical trials stall, and Americans pay the price while regulators haggle. In other words, we could be held hostage by logistics and regulation rather than rockets.
What Congress and the White House are doing — and what they must do
Lawmakers and some agencies have started to act. The NSCEB report and now the CFR study have pushed bills and rules to tighten procurement, screen synthetic-DNA orders, and invest in U.S. biomanufacturing. Senator Todd Young and others are pressing for laws to reduce risky buying and to build domestic capacity. That’s good. It’s not enough. We need fast funding for factories, clearer agency rules to bar risky suppliers, and real incentives for private companies to reshore critical production. Throwing money at feel-good programs won’t cut it if the plants and oversight aren’t there.
Bottom line: stop pretending this is someone else’s problem
For years we let cheap supply win over common sense. That saved insurers a buck but hollowed out our ability to make life-saving medicines. If you care about national security, veterans’ care, or grandma’s prescriptions, this is not an academic debate. The CFR report gives us a clear wake-up call. Congress and the Administration must act, not with speeches, but with money, rules and muscle. Otherwise we’ll trade freedom for a cheaper pill. That is a bargain no conservative should accept — and no American should tolerate.
